Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

News Update


Animal Health Product Developer to Expand Sales Footprint
News Update

Share on Stocktwits


This Canadian company makes progress with its commercial uptake efforts.

Avivagen Inc. (VIV:TSX.V) will add another country to its geographical sales footprint through a new partnership, with Viphavet Co. Ltd., to sell Vivamune Health Chews in Vietnam. Vivamune is a chewable for animals that contains Avivagen's proprietary OxC-beta that "targets joint, skin and digestive health," noted the news release.

According to the distribution agreement, Viphavet will register and trademark Vivamune Health Chews within Vietnam. Once done, likely by year-end 2018, the distributor gains exclusivity on the product for one year with further extensions possible as it reaches certain sales milestones. The company, based in Ho Chi Minh City, distributes animal vaccines and pharmaceuticals along with veterinary equipment.

Avivagen, following up on the interest in Vietnam for its Vivamune, plans to shortly "pursue market uptake initiatives" there for its OxC-beta Livestock product, the release said.


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Avivagen. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, a company mentioned in this article.

Want to read more about Nutraceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe